<DOC>
	<DOCNO>NCT02634931</DOCNO>
	<brief_summary>The purpose trial evaluate safety efficacy long-term treatment NPC-12G gel ( 0.2 % sirolimus gel ) angiofibroma skin lesion patient tuberous sclerosis complex open-label trial .</brief_summary>
	<brief_title>Long-term Trial Topical Sirolimus Angiofibroma Patient With Tuberous Sclerosis Complex</brief_title>
	<detailed_description>Tuberous Sclerosis Complex ( TSC ) autosomal dominant hereditary disease cause benign tumor almost whole body ( include skin , brain , kidney , lung heart ) , behavior disorder autism , mental retardation neurologic symptom epilepsy . Angiofibroma TSC-specific facial skin lesion , hamartoma cause increase component skin connective tissue blood vessel . Other skin lesion due TSC white macule ( hypomelanotic macule ) , plaque , shagreen patch ungual fibroma . Current therapeutic method angiofibroma laser surgical treatment , problem many relapse , deficiency evidence , change pigment , scar risk infection . This multicenter open-label trial . The trial consist two phase . In first trial phase 52 week , efficacy well safety evaluate . For second trial phase trial continue date approval NDA NPC-12G . The safety evaluate second trial phase , efficacy . Patients meet entry criterion trial apply 0.2 % NPC-12G gel twice day . Patients visit 4 5-week interval first 6 month first trial phase , 3 month interval thereafter .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiofibroma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male female patient 3 year old great time inform consent 2 . Patients diagnose definite diagnosis accord diagnostic criterion tuberous sclerosis complex ( International Tuberous Sclerosis Complex Consensus Conference 2012 ) 3 . Patients skin lesion angiofibroma , white macule plaque upper neck associate tuberous sclerosis complex screen visit baseline visit 4 . Patients his/her guardian agree use test drug ( NPC12G gel ) want participate trial follow participation Phase III trial ( NPC12G1 ) 5 . Patient consider appropriate patient participate trial investigator 6 . Patients his/her guardian give write informed consent understand willingness receive enough explanation test drug current trial plan 1 . Patients offer withdraw Phase III trial ( NPC12G1 ) discontinue 2 . Patients applied test drug topically 25 % whole application without appropriate reason Phase III trial ( NPC12G1 ) 3 . Patients clinical finding erosion , ulcer eruption around lesion angiofibroma , may affect assessment safety efficacy 4 . Patients history hypersensitivity alcohol allergy sirolimus 5 . Patients complication malignant tumor , infection , serious heart disease , hepatic function disorder , renal function disorder blood disorder severity consider investigator grade 2 severe reference `` Concerning classification criterion seriousness adverse drug reaction medical agent '' 6 . Patients complication disease unsuitable trial participation , example , uncontrolled diabetes ( fast blood glucose level &gt; 140 mg/dL postprandial blood glucose level &gt; 200 mg/dL ) , dyslipidemia ( cholesterol level &gt; 300 mg/dL &gt; 7.75 mmol/L , triglyceride level &gt; 300 mg/dL &gt; 3.42 mmol/L ) , etc . 7 . Female patient may pregnancy lactate 8 . Patients agree take appropriate measure contraception completion trial followup period discontinuation inform consent 9 . Patients participate clinical trial Phase III trial ( NPC12G1 ) take trial drug within 6 month inform consent 10 . Others , patient consider investigator unsuitable participation trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Skin lesion</keyword>
	<keyword>TSC</keyword>
	<keyword>Tuberous Sclerosis Complex</keyword>
	<keyword>NPC-12G</keyword>
	<keyword>Angiofibroma</keyword>
	<keyword>Hypomelanotic Macule</keyword>
	<keyword>Plaque</keyword>
</DOC>